Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06668935

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

Sponsor: Abbott Diabetes Care

View on ClinicalTrials.gov

Summary

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

800

Start Date

2024-10-24

Completion Date

2027-12

Last Updated

2026-10-27

Healthy Volunteers

No

Interventions

DEVICE

To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists

All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.

Locations (8)

Helios Clinical Research

Paradise Valley, Arizona, United States

East Coast Institute for Research, LLC

Jacksonville, Florida, United States

Excellence Medical and Research

Miami Gardens, Florida, United States

American Research Centers of Florida

Pembroke Pines, Florida, United States

Cross Creek Medical Clinic, PA

Fayetteville, North Carolina, United States

Medication Management

Greensboro, North Carolina, United States

M3 Wake Research, Inc

Dallas, Texas, United States

Care United Research

Forney, Texas, United States